Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the Phase 1 EXPLORER (NCT0256198) and Phase 2 PATHFINDER (NCT03580655) trials (N =...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiter, Andreas, Gotlib, Jason, Álvarez-Twose, Iván, Radia, Deepti H., Lübke, Johannes, Bobbili, Priyanka J., Wang, Aolin, Norregaard, Chelsea, Dimitrijevic, Saša, Sullivan, Erin, Louie-Gao, Melinda, Schwaab, Juliana, Galinsky, Ilene A., Perkins, Cecelia, Sperr, Wolfgang R., Sriskandarajah, Priya, Chin, Andi, Sendhil, Selvam R., Duh, Mei Sheng, Valent, Peter, DeAngelo, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343245/
https://www.ncbi.nlm.nih.gov/pubmed/35790816
http://dx.doi.org/10.1038/s41375-022-01615-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343245/
https://www.ncbi.nlm.nih.gov/pubmed/35790816
http://dx.doi.org/10.1038/s41375-022-01615-z

Ejemplares similares